Literature DB >> 11248528

Activity and spectrum of BMS 284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci.

R N Jones1, M A Pfaller, M Stilwell.   

Abstract

BMS 284756, a novel des-fluoroquinolone with an expanded potency versus Gram-positive pathogens, demonstrated potent activity against a wide range of 3,541 ciprofloxacin-resistant (MIC, > or = 2 microg/ml) Gram-positive cocci. These strains were selected from more than 24,000 isolates gathered as part of the 1999 SENTRY Antimicrobial Surveillance Program. Further clinical development appears warranted.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11248528     DOI： 10.1016/s0732-8893(00)00233-9

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  7 in total

1.  Antimicrobial activities of BMS-284756 compared with those of fluoroquinolones and beta-lactams against gram-positive clinical isolates.

Authors:  Matteo Bassetti; Louise M Dembry; Patricia A Farrel; Deborah A Callan; Vincent T Andriole
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

Review 2.  Gatifloxacin: a review of its use in the management of bacterial infections.

Authors:  Caroline M Perry; Douglas Ormrod; Miriam Hurst; Susan V Onrust
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.

Authors:  Dilek Ince; Xiamei Zhang; L Christine Silver; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

4.  Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus.

Authors:  Xilin Zhao; William Eisner; Nathan Perl-Rosenthal; Barry Kreiswirth; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

5.  Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects.

Authors:  D A Gajjar; A Bello; Z Ge; L Christopher; D M Grasela
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

6.  Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci.

Authors:  José M Entenza; Jacques Vouillamoz; Michel P Glauser; Philippe Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

7.  Activities of garenoxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.

Authors:  E Azoulay-Dupuis; J P Bédos; J Mohler; G Peytavin; R Isturiz; P Moine; V Rieux; C Cherbuliez; J C Péchère; B Fantin; T Köhler
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.